Joaquim Bellmunt

Summary

Affiliation: Hospital del Mar
Country: Spain

Publications

  1. doi request reprint The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations
    Joaquim Bellmunt
    University Hospital del Mar, Barcelona, Spain
    BJU Int 103:572-7. 2009
  2. ncbi request reprint Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    J Bellmunt
    Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 18:522-8. 2007
  3. ncbi request reprint Sorafenib TARGET trial results in Spanish patients
    J Bellmunt
    Servicio de Oncología Hospital General Universitari Vall d Hebrón Barcelona, Spain
    Clin Transl Oncol 9:671-3. 2007
  4. ncbi request reprint Predictive modelling in hormone-refractory prostate cancer (HRPC)
    J Bellmunt
    Department of Medical Oncology, University Hospital del Mar IMIM, Barcelona, Spain
    Clin Transl Oncol 11:82-5. 2009
  5. doi request reprint Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
    Joaquim Bellmunt
    Medical Oncology Service, Hospital del Mar, Passeig Maritim 25, 08003 Barcelona, Spain
    Cancer Chemother Pharmacol 63:S1-13. 2009
  6. pmc Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA
    Virginia Lopez
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Melchor Fernandez Almagro 3, Madrid E 28029, Spain
    J Transl Med 11:182. 2013
  7. doi request reprint A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    BJU Int 107:1190-9. 2011
  8. doi request reprint Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents
    J Bellmunt
    Medical Oncology Service, Hospital del Mar IMAS, Experimental Cancer Therapeutics Unit URTEC IMIM H del Mar, Barcelona, Spain
    Crit Rev Oncol Hematol 69:211-22. 2009
  9. doi request reprint The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    Crit Rev Oncol Hematol 69:64-72. 2009
  10. doi request reprint Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
    Joaquim Bellmunt
    Department of Oncology, Lund University Hospital, Lund, Sweden
    BJU Int 104:10-8. 2009

Detail Information

Publications44

  1. doi request reprint The medical management of metastatic renal cell carcinoma: integrating new guidelines and recommendations
    Joaquim Bellmunt
    University Hospital del Mar, Barcelona, Spain
    BJU Int 103:572-7. 2009
    ..In these circumstances, less well-controlled sources of data, and clinical experience, have a role to play. Certain guidelines (although not all) acknowledge the contribution that such sources of evidence can make...
  2. ncbi request reprint Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy
    J Bellmunt
    Vall d Hebron University Hospital, Barcelona, Spain
    Ann Oncol 18:522-8. 2007
    ..Since DNA damaging agents are the cornerstones of therapy, we hypothesized that levels of DNA repair genes could predict survival...
  3. ncbi request reprint Sorafenib TARGET trial results in Spanish patients
    J Bellmunt
    Servicio de Oncología Hospital General Universitari Vall d Hebrón Barcelona, Spain
    Clin Transl Oncol 9:671-3. 2007
    ..The aim of this study is to report the results of the patients included in the Spanish centres in this trial...
  4. ncbi request reprint Predictive modelling in hormone-refractory prostate cancer (HRPC)
    J Bellmunt
    Department of Medical Oncology, University Hospital del Mar IMIM, Barcelona, Spain
    Clin Transl Oncol 11:82-5. 2009
    ..This nomogram will be a helpful tool to stratify patients for further docetaxel-based trials and could also help us to delineate the potential benefits of chemotherapy at certain points during the natural history of HRPC...
  5. doi request reprint Recommendations from the Spanish Oncology Genitourinary Group for the treatment of metastatic renal cancer
    Joaquim Bellmunt
    Medical Oncology Service, Hospital del Mar, Passeig Maritim 25, 08003 Barcelona, Spain
    Cancer Chemother Pharmacol 63:S1-13. 2009
    ..Based on this previous work, a treatment algorithm was developed...
  6. pmc Identification of prefoldin amplification (1q23.3-q24.1) in bladder cancer using comparative genomic hybridization (CGH) arrays of urinary DNA
    Virginia Lopez
    Tumor Markers Group, Molecular Pathology Program, Spanish National Cancer Center, Melchor Fernandez Almagro 3, Madrid E 28029, Spain
    J Transl Med 11:182. 2013
    ..Array-CGH represents a comprehensive tool to discover genomic disease alterations that could potentially be applied to body fluids. In this report, we aimed at applying array-CGH to urinary samples to characterize bladder cancer...
  7. doi request reprint A new patient-focused approach to the treatment of metastatic renal cell carcinoma: establishing customized treatment options
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    BJU Int 107:1190-9. 2011
    ..This patient-focused approach has broad application to other agents and tumour types...
  8. doi request reprint Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents
    J Bellmunt
    Medical Oncology Service, Hospital del Mar IMAS, Experimental Cancer Therapeutics Unit URTEC IMIM H del Mar, Barcelona, Spain
    Crit Rev Oncol Hematol 69:211-22. 2009
    ..Finally, chemotherapy optimization using clinical and molecular markers predicting chemosensitivity and prognosis are emerging...
  9. doi request reprint The medical treatment of metastatic renal cell cancer in the elderly: position paper of a SIOG Taskforce
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    Crit Rev Oncol Hematol 69:64-72. 2009
    ..Meanwhile, when considering the most appropriate drug to use in a particular patient, the toxicity profiles of the individual targeted agents--and any implications for specific comorbid conditions--should be taken into account...
  10. doi request reprint Optimal management of metastatic renal cell carcinoma: an algorithm for treatment
    Joaquim Bellmunt
    Department of Oncology, Lund University Hospital, Lund, Sweden
    BJU Int 104:10-8. 2009
    ..As our understanding of the activity of targeted agents for mRCC increases, we should ensure that these agents are used appropriately to provide patients with optimal treatment benefits...
  11. doi request reprint Future developments in renal cell carcinoma
    J Bellmunt
    Solid Tumor Oncology Genitourinary and Gastrointestinal Section, Medical Oncology Service, Hospital del Mar, Barcelona, Spain
    Ann Oncol 20:i13-17. 2009
    ....
  12. doi request reprint Impact of PSA implementation and combined radiation and hormonal therapy (RT+HT) on outcome of prostate cancer patients
    Joaquim Bellmunt
    Department of Medical Oncology, Hospital Universitari del Mar IMIM Passeig Marítim 25 29, Barcelona E 08003, Spain
    Eur J Cancer 45:2804-9. 2009
    ..Besides other factors, changes in death rates since 1999 could be explained by secular variations in the treatment of the disease, particularly the implementation of RT+HT in intermediate and high-risk locally advanced prostate cancer...
  13. doi request reprint Phase III trial of vinflunine plus best supportive care compared with best supportive care alone after a platinum-containing regimen in patients with advanced transitional cell carcinoma of the urothelial tract
    Joaquim Bellmunt
    Department of Medical Oncology, University Hospital del Mar, Passeig Maritim 25 29, E 08003 Barcelona, Spain
    J Clin Oncol 27:4454-61. 2009
    ..We conducted a randomized phase III study of VFL and best supportive care (BSC) versus BSC alone in the treatment of patients with advanced TCCU who had experienced progression after a first-line platinum-containing regimen...
  14. doi request reprint Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06)
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar IMIM, Barcelona, Spain
    Lancet Oncol 11:350-7. 2010
    ..This multicentre, phase 2 study investigated the effectiveness of MTD gemcitabine combined with metronomic capecitabine plus the multikinase inhibitor sorafenib for the treatment of metastatic renal-cell carcinoma (RCC)...
  15. doi request reprint Prognostic factors in patients with advanced transitional cell carcinoma of the urothelial tract experiencing treatment failure with platinum-containing regimens
    Joaquim Bellmunt
    Department of Medical Oncology, University Hospital del Mar, Passeig Maritim 25 29, E 08003 Barcelona, Spain
    J Clin Oncol 28:1850-5. 2010
    ..These factors, together with low hemoglobin, can be used for prognostication and future patient stratification in clinical trials...
  16. doi request reprint Experience with sorafenib and adverse event management
    Joaquim Bellmunt
    Solid Tumor Oncology Section, Medical Oncology Service, University Hospital del Mar IMIM, Barcelona, Spain
    Crit Rev Oncol Hematol 78:24-32. 2011
    ..In addition, general recommendations for dose modifications are discussed. The goal of these management recommendations is to optimize sorafenib therapy for advanced RCC...
  17. doi request reprint Expert opinion on the use of first-line sorafenib in selected metastatic renal cell carcinoma patients
    Joaquim Bellmunt
    University Hospital del Mar IMIM, RTICC, Paseo Maritimi 25 29, Barcelona, Spain
    Expert Rev Anticancer Ther 10:825-35. 2010
    ..Based on our clinical experience in treating patients with renal cell carcinoma, this article offers our opinions on factors that characterize patients for whom sorafenib may serve as a viable first-line therapeutic option...
  18. doi request reprint A phase II trial of first-line sorafenib in patients with metastatic renal cell carcinoma unwilling to receive or with early intolerance to immunotherapy: SOGUG Study 06-01
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    Clin Transl Oncol 12:503-8. 2010
    ..Our aim was to evaluate first-line treatment of metastatic renal cell carcinoma (mRCC) with sorafenib in patients unwilling to receive immunotherapy or with early intolerance to immunotherapy...
  19. doi request reprint Clinical activity of vinflunine in transitional cell carcinoma of the urothelium and other solid tumors
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar, Paseo Maritimo 25 29, Barcelona, Spain
    Semin Oncol 35:S34-43. 2008
    ..The activity and tolerability of this agent warrant further investigation. Phase 3 trials are underway to further define the extent of clinical benefit provided by vinflunine in patients with advanced solid malignancies...
  20. doi request reprint Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features
    J Bellmunt
    Oncology Department, University Hospital del Mar, Barcelona, Spain
    Ann Oncol 19:1387-92. 2008
    ....
  21. ncbi request reprint Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents
    Joaquim Bellmunt
    Oncology Department, Hospital del Mar, Barcelona, Spain
    BJU Int 99:274-80. 2007
    ....
  22. ncbi request reprint Chemotherapy for metastatic or unresectable bladder cancer
    Joaquim Bellmunt
    Hospital del Mar IMAS, Autonoma University of Barcelona, Barcelona, Spain
    Semin Oncol 34:135-44. 2007
    ..In addition to new active drug combinations and targeted therapies, chemotherapy optimization using molecular characteristics to predict chemosensitivity is emerging...
  23. ncbi request reprint Medical management of advanced prostate cancer: a multidisciplinary team approach
    Joaquim Bellmunt Molins
    Hospital del Mar, Solid Tumor Oncology GU and GI Medical Oncology Service, Barcelona, Spain
    Expert Rev Anticancer Ther 7:977-9. 2007
  24. ncbi request reprint Intermittent chemotherapy in metastatic androgen-independent prostate cancer
    Joaquim Bellmunt
    Medical Oncology Service Hospital del Mar IMAS, Experimental Cancer Therapeutics Unit URTEC IMIM H del Mar, Barcelona, Spain
    BJU Int 100:490-2. 2007
  25. doi request reprint New agents for bladder cancer
    J Bellmunt
    University Hospital del Mar, Barcelona, Spain
    Ann Oncol 21:vii56-8. 2010
    ..Results from recent and ongoing trials suggest that some of these agents could soon emerge as useful players to overcome the limitations of our present therapies...
  26. ncbi request reprint Pretreatment prognostic factors for survival in patients with advanced urothelial tumors treated in a phase I/II trial with paclitaxel, cisplatin, and gemcitabine
    Joaquim Bellmunt
    Medical Oncology Sevice, Vall d Hebron University Hospital, Barcelona, Spain
    Cancer 95:751-7. 2002
    ....
  27. pmc Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine and gemcitabine/cisplatin in patients with locally advanced or metastatic urothelial cancer without prior systemic therapy: EORTC Intergroup Study 30987
    Joaquim Bellmunt
    Vall d Hebron University Hospital, Barcelona, Spain
    J Clin Oncol 30:1107-13. 2012
    ..A phase I/II study suggested that a three-drug regimen that included paclitaxel had greater antitumor activity and might improve survival...
  28. doi request reprint Cisplatin and gemcitabine administered every two weeks in patients with locally advanced or metastatic urothelial carcinoma and impaired renal function
    Rafael Morales-Barrera
    Department of Medical Oncology, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Catalonia, Spain
    Eur J Cancer 48:1816-21. 2012
    ..However, standard dose schedule of cisplatin cannot be used in patients with impaired renal function. We evaluated the safety and efficacy of gemcitabine and a split dose administration of cisplatin in patients with renal dysfunction...
  29. doi request reprint Advances in the management of high-risk localised and metastatic prostate cancer
    Joaquim Bellmunt
    Medical Oncology Service, University Hospital del Mar IMIM, Barcelona, Spain
    BJU Int 109:8-13. 2012
    ..To ensure optimal patient care, early and continuous involvement of the multidisciplinary team will be required...
  30. doi request reprint Variant forms of bladder cancer: basic considerations on treatment approaches
    Francesc Pons
    Medical Oncology Service, University Hospital del Mar, Barcelona, Spain
    Curr Oncol Rep 13:216-21. 2011
    ..In the present report, existent literature about variant forms of bladder cancer is reviewed with focus on the most frequent: squamous cell, adenocarcinoma, small cell, micropapillary, sarcomatoid, and lymphoepithelioma-like...
  31. ncbi request reprint Phase I pharmacokinetic and pharmacodynamic study of weekly 1-hour and 24-hour infusion BMS-214662, a farnesyltransferase inhibitor, in patients with advanced solid tumors
    Josep Tabernero
    Medical Oncology Department, Vall d Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain corrected
    J Clin Oncol 23:2521-33. 2005
    ....
  32. doi request reprint Molecular determinants of response to cisplatin-based neoadjuvant chemotherapy
    Joaquim Bellmunt
    aLaboratoy Recerca IMIM University Hospital del Mar, Barcelona, Spain and Dana Farber Brigham and Women s Cancer Center, Harvard Medical School, Boston, Massachusetts bDepartment of Medical Oncology, Hospital del Mar cDepartment of Urology, Hospital Vall d Hebron, Barcelona, Spain
    Curr Opin Urol 23:466-71. 2013
    ..We present the currently available data outlining a variety of potential markers to aid for a personalized decision-making process...
  33. doi request reprint New therapeutic challenges in advanced bladder cancer
    Joaquim Bellmunt
    Medical Oncology Service, Parc de Salut Mar, Universitat Autonoma de Barcelona, Barcelona, Spain
    Semin Oncol 39:598-607. 2012
    ..Understanding the set of changes at the individual patient level hopefully will enable personalized treatment for patients with urothelial cancer...
  34. doi request reprint Identification of a mutation in the extracellular domain of the Epidermal Growth Factor Receptor conferring cetuximab resistance in colorectal cancer
    Clara Montagut
    Department of Medical Oncology, Hospital del Mar, Barcelona, Spain
    Nat Med 18:221-3. 2012
    ..Two of ten subjects studied here with disease progression after cetuximab treatment acquired this mutation. A subject with cetuximab resistance harboring the S492R mutation responded to treatment with panitumumab...
  35. doi request reprint Practical aspects of metastatic castration-resistant prostate cancer management: patient case studies
    Amit Bahl
    Bristol Haematology and Oncology Centre, University Hospitals Bristol, UK
    BJU Int 109:14-9. 2012
    ..The development of second-line chemotherapeutic agents together with the use of prognostic factors and a patient-centred multidisciplinary team approach provide encouraging new management prospects for patients with mCRPC...
  36. ncbi request reprint Open-label phase II study evaluating the efficacy and safety of two doses of pertuzumab in castrate chemotherapy-naive patients with hormone-refractory prostate cancer
    Johann Sebastian de Bono
    Drug Development Unit and Department of Academic Urology, Royal Marsden Hospital, Centre for Cancer Therapeutics, Institute for Cancer Research, Surrey, United Kingdom
    J Clin Oncol 25:257-62. 2007
    ..To determine the prostate-specific antigen (PSA) 50% decline rate within 24 weeks of starting treatment with single-agent pertuzumab in castrate patients with hormone-refractory prostate cancer (HRPC)...
  37. ncbi request reprint The medical management of prostate cancer: a multidisciplinary team approach
    Cora N Sternberg
    Department of Medical Oncology, San Camillo Forlanini Hospital, Rome, Italy
    BJU Int 99:22-7. 2007
  38. ncbi request reprint Estrogen receptor beta displays cell cycle-dependent expression and regulates the G1 phase through a non-genomic mechanism in prostate carcinoma cells
    Antoni Hurtado
    Unitat de Recerca Biomedica, Institut de Recerca, Hospital Universitari Vall d Hebron, 8035 Barcelona, Spain
    Cell Oncol 30:349-65. 2008
    ..It is well known that estrogens regulate cell cycle progression, but the specific contributions and mechanisms of action of the estrogen receptor beta (ERbeta) remain elusive...
  39. ncbi request reprint Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer
    Cora N Sternberg
    Department of Oncology, San Camillo Forlanini Hospital, Rome, Italy
    Urology 69:62-79. 2007
    ....
  40. ncbi request reprint Chemotherapy for older patients with prostate cancer
    John Anderson
    Department of Urology, University Hospital KU Leuven, Belgium
    BJU Int 99:269-73. 2007
  41. ncbi request reprint [Current strategies in the treatment of renal-cell cancer: targeted therapies]
    Jose Manuel Trigo
    Servicio de Oncologia Medica, Hospital Universitario Virgen de la Victoria, Malaga, Espana
    Med Clin (Barc) 130:380-92. 2008
    ..Many of these targeted therapies, especially sunitinib, have demonstrated significant activity in kidney cancer clinical trials and represent a substantive advance in the treatment of this disease...
  42. ncbi request reprint [Advanced bladder cancer: new therapeutic strategies]
    Santiago Albiol
    Unidad de Oncologia, Clinica Quiron, Barcelona, Espana
    Med Clin (Barc) 120:68-77. 2003
  43. ncbi request reprint Overview of gemcitabine triplets in metastatic bladder cancer
    Ronald de Wit
    Department of Medical Oncology, Rotterdam Cancer Institute Daniel den Hoed Kliniek, University Hospital Rotterdam, P O Box 5201, 3008 AE, Rotterdam, The Netherlands
    Crit Rev Oncol Hematol 45:191-7. 2003
    ..A randomized study of the paclitaxel-cisplatin-gemcitabine triplet versus gemcitabine-cisplatin is ongoing...
  44. ncbi request reprint Hepatitis A virus receptor blocks cell differentiation and is overexpressed in clear cell renal cell carcinoma
    Maya R Vila
    Centre d Investigacions en Bioquimica i Biologia Molecular CIBBIM, Hospital Universitari Vall d Hebron, Barcelona Spain
    Kidney Int 65:1761-73. 2004
    ..The molecular mechanisms underlying tumorigenesis and progression of clear cell renal cell carcinoma (ccRCC) are not well understood. We aimed to identify new molecular markers to provide insight into these processes...